Panzyga®

What is panzyga^®?

panzyga^® is a high purity 10% human normal intravenous immunoglobulin solution (IVIg) derived from donated human plasma.¹ While panzyga^® uses glycine as a stabilizer, its precisely developed formulation and resulting product profile allows for rapid infusion rates without compromising tolerability.^1-5 Although the mechanism of action of panzyga^® in each specific indication is not fully elucidated, adequate doses of IVIg have been clinically shown to:

Restore abnormally low IgG levels in patients affected by primary and secondary immunodeficiencies.

Exert anti-inflammatory and immunomodulatory activities in autoimmune or neurological disorders.

About panzyga®

panzyga^®indications

panzyga^® is approved for use across a range of clinical indications, providing proven clinical evidence, experience and confidence to support healthcare professionals, patients and caregivers.

panzyga® is indicated for both replacement therapy in patients with primary and secondary immunodeficiencies (PID, SID) and for immunomodulation in specific autoimmune and neurological disorders.1

Dosing recommendations

Driven by Clinical Research for Optimal Treatment Results

Demonstrated clinical efficacy and tolerability in PID, ITP and CIDP.

Learn more about it efficacy and tolerability

Easy, convenient and reliable.

The colour coding of panzyga® vials, together with their variety of presentations and storage at room temperature, ensures practical, convenient and reliable administration.

References

Panzyga® Summary of Product Characteristics
Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29. PMID: 28755067; PMCID: PMC5554470. [PubMed]
Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022 Apr 29;145(3):887-896. doi: 10.1093/brain/awab422. PMID: 35038723; PMCID: PMC9050528. [PubMed]
Ochs HD, Melamed I, Borte M, Moy JN, Pyringer B, D Kobayashi AL, Knutsen AP, Smits W, Pituch-Noworolska A, Kobayashi RH. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 Oct;10(14):1193-1202. doi: 10.2217/imt-2018-0074. Epub 2018 Aug 8. PMID: 30088423. [PubMed]
Mersich C, Ahrer K, Buchacher A, Ernegger T, Kohla G, Kannicht C, Pock K, Römisch J. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga^®). Biologicals. 2017 Jan;45:33-38. doi: 10.1016/j.biologicals.2016.10.003. Epub 2016 Oct 27. PMID: 28341308. [PubMed]
Matucci A, Maggi E, Vultaggio A. Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. Front Immunol. 2015 Jan 12;5:690. doi: 10.3389/fimmu.2014.00690. PMID: 25628625; PMCID: PMC4290674. [PubMed]
Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi: 10.1007/s13311-021-01108-4. Epub 2021 Nov 11. PMID: 34766257; PMCID: PMC8585501. [PubMed]

Looking to the future